94 related articles for article (PubMed ID: 15889158)
1. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Jørgensen HG; Allan EK; Graham SM; Godden JL; Richmond L; Elliott MA; Mountford JC; Eaves CJ; Holyoake TL
Leukemia; 2005 Jul; 19(7):1184-91. PubMed ID: 15889158
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
5. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
7. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
Jørgensen HG; Allan EK; Mountford JC; Richmond L; Harrison S; Elliott MA; Holyoake TL
Exp Hematol; 2005 Oct; 33(10):1140-6. PubMed ID: 16219536
[TBL] [Abstract][Full Text] [Related]
8. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J
Cancer; 2006 Jan; 106(2):346-52. PubMed ID: 16342165
[TBL] [Abstract][Full Text] [Related]
10. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.
Jordanides NE; Jorgensen HG; Holyoake TL; Mountford JC
Blood; 2006 Aug; 108(4):1370-3. PubMed ID: 16627755
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.
Palamà IE; Leporatti S; de Luca E; Di Renzo N; Maffia M; Gambacorti-Passerini C; Rinaldi R; Gigli G; Cingolani R; Coluccia AM
Nanomedicine (Lond); 2010 Apr; 5(3):419-31. PubMed ID: 20394535
[TBL] [Abstract][Full Text] [Related]
12. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
13. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Hoover RR; Mahon FX; Melo JV; Daley GQ
Blood; 2002 Aug; 100(3):1068-71. PubMed ID: 12130526
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
[TBL] [Abstract][Full Text] [Related]
16. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Tipping AJ; Mahon FX; Zafirides G; Lagarde V; Goldman JM; Melo JV
Leukemia; 2002 Dec; 16(12):2349-57. PubMed ID: 12454739
[TBL] [Abstract][Full Text] [Related]
17. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Holtz MS; Forman SJ; Bhatia R
Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.
Jørgensen HG; Allan EK; Jordanides NE; Mountford JC; Holyoake TL
Blood; 2007 May; 109(9):4016-9. PubMed ID: 17213283
[TBL] [Abstract][Full Text] [Related]
20. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
Jiang X; Forrest D; Nicolini F; Turhan A; Guilhot J; Yip C; Holyoake T; Jorgensen H; Lambie K; Saw KM; Pang E; Vukovic R; Lehn P; Ringrose A; Yu M; Brinkman RR; Smith C; Eaves A; Eaves C
Blood; 2010 Sep; 116(12):2112-21. PubMed ID: 20574046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
